Nurix Therapeutics (NRIX) Financials

$9.67 -0.47 (-4.64%)

Closing price 04:00 PM Eastern

Extended Trading

$9.67 0.00 (0.00%)

As of 05:46 PM Eastern

Annual Income Statements for Nurix Therapeutics

This table shows Nurix Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	11/30/2019	11/30/2020	11/30/2021	11/30/2022	11/30/2023	11/30/2024
Net Income / (Loss) Attributable to Common Shareholders	-22	-43	-117	-180	-144	-194
Consolidated Net Income / (Loss)	-22	-43	-117	-180	-144	-194
Net Income / (Loss) Continuing Operations	-22	-43	-117	-180	-144	-194
Total Pre-Tax Income	-21	-64	-117	-180	-144	-193
Total Operating Income	-22	-65	-118	-184	-155	-213
Total Gross Profit	31	18	30	39	77	55
Total Revenue	31	18	30	39	77	55
Operating Revenue	31	18	30	39	77	55
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	53	83	148	222	232	268
Selling, General & Admin Expense	8.33	16	31	38	43	46
Research & Development Expense	45	66	116	184	189	222
Total Other Income / (Expense), net	0.78	1.21	0.82	3.51	11	20
Interest & Investment Income	0.78	1.21	0.82	3.51	11	20
Income Tax Expense	0.24	-21	0.13	0.00	0.00	0.27
Basic Earnings per Share	($6.59)	($2.76)	($2.73)	($3.71)	($2.65)	($2.88)
Weighted Average Basic Shares Outstanding	3.29M	15.67M	42.90M	48.61M	54.34M	67.12M
Diluted Earnings per Share	($6.59)	($2.76)	($2.73)	($3.71)	($2.65)	($2.88)
Weighted Average Diluted Shares Outstanding	3.29M	15.67M	42.90M	48.61M	54.34M	67.12M
Weighted Average Basic & Diluted Shares Outstanding	3.29M	15.67M	42.90M	47.27M	48.89M	75.89M
Cash Dividends to Common per Share	$0.00	$0.00	-	-	-	$0.00

This table shows Nurix Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	11/30/2022	2/28/2023	5/31/2023	8/31/2023	11/30/2023	2/29/2024	5/31/2024	8/31/2024	11/30/2024	2/28/2025	5/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-47	-41	-24	-37	-42	-42	-45	-49	-59	-56	-43
Consolidated Net Income / (Loss)	-47	-41	-24	-37	-42	-42	-45	-49	-59	-56	-43
Net Income / (Loss) Continuing Operations	-47	-41	-24	-37	-42	-42	-45	-49	-59	-56	-43
Total Pre-Tax Income	-47	-41	-24	-37	-42	-41	-44	-49	-59	-56	-43
Total Operating Income	-49	-43	-27	-40	-45	-45	-49	-55	-65	-63	-48
Total Gross Profit	6.78	13	31	18	15	17	12	13	13	18	44
Total Revenue	6.78	13	31	18	15	17	12	13	13	18	44
Operating Revenue	6.78	-	31	18	-	17	12	13	-	18	44
Total Cost of Revenue	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00	0.00
Total Operating Expenses	55	56	57	58	60	62	61	67	78	81	92
Selling, General & Admin Expense	9.37	9.82	12	11	11	12	12	12	11	12	14
Research & Development Expense	46	46	46	48	50	50	49	55	67	70	78
Total Other Income / (Expense), net	1.97	2.22	2.49	3.03	3.38	3.79	4.08	5.74	6.12	6.51	5.62
Interest & Investment Income	1.97	2.22	2.49	3.03	3.38	3.79	4.08	5.74	6.12	6.51	5.62
Income Tax Expense	-	0.00	0.00	0.00	-	0.09	0.09	0.08	0.01	0.00	0.76
Basic Earnings per Share	($0.85)	($0.75)	($0.45)	($0.68)	($0.77)	($0.76)	($0.71)	($0.67)	($0.74)	($0.67)	($0.52)
Weighted Average Basic Shares Outstanding	48.61M	54.03M	54.26M	54.39M	54.34M	54.90M	62.38M	72.78M	67.12M	83.56M	83.88M
Diluted Earnings per Share	($0.85)	($0.75)	($0.45)	($0.68)	($0.77)	($0.76)	($0.71)	($0.67)	($0.74)	($0.67)	($0.52)
Weighted Average Diluted Shares Outstanding	48.61M	54.03M	54.26M	54.39M	54.34M	54.90M	62.38M	72.78M	67.12M	83.56M	83.88M
Weighted Average Basic & Diluted Shares Outstanding	47.27M	47.45M	48.20M	48.50M	48.89M	49.15M	64.41M	70.84M	75.89M	76.24M	76.45M

This table details how cash moves in and out of Nurix Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	11/30/2019	11/30/2020	11/30/2021	11/30/2022	11/30/2023	11/30/2024
Net Change in Cash & Equivalents	9.23	85	-39	-15	-9.85	55
Net Cash From Operating Activities	0.60	-0.08	-84	-160	-81	-173
Net Cash From Continuing Operating Activities	0.60	-0.08	-84	-160	-81	-173
Net Income / (Loss) Continuing Operations	-22	-43	-117	-180	-144	-194
Consolidated Net Income / (Loss)	-22	-43	-117	-180	-144	-194
Depreciation Expense	2.35	2.18	2.79	5.35	7.53	9.32
Amortization Expense	-0.11	0.27	5.00	5.89	0.70	-4.18
Non-Cash Adjustments To Reconcile Net Income	0.51	-3.20	16	28	34	34
Changes in Operating Assets and Liabilities, net	20	44	9.11	-19	20	-18
Net Cash From Investing Activities	8.50	-254	-108	27	68	-258
Net Cash From Continuing Investing Activities	8.50	-254	-108	27	68	-258
Purchase of Property, Plant & Equipment	-1.65	-4.55	-5.66	-12	-8.40	-9.27
Purchase of Investments	-9.35	-275	-348	-239	-246	-708
Sale and/or Maturity of Investments	20	25	246	279	323	460
Net Cash From Financing Activities	0.13	339	154	117	3.22	486
Net Cash From Continuing Financing Activities	0.13	339	154	117	3.22	486
Repurchase of Preferred Equity	-0.02	-	-0.00	0.00	0.00	-0.02
Issuance of Common Equity	0.00	218	152	116	2.23	481
Other Financing Activities, net	0.14	0.97	1.67	1.08	0.99	5.06

This table details how cash moves in and out of Nurix Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	11/30/2022	2/28/2023	5/31/2023	8/31/2023	11/30/2023	2/29/2024	5/31/2024	8/31/2024	11/30/2024	2/28/2025	5/31/2025
Net Change in Cash & Equivalents	17	-31	25	-17	12	-4.81	67	-18	11	-34	8.34
Net Cash From Operating Activities	-38	-48	-18	-41	27	-42	-40	-42	-49	-61	-63
Net Cash From Continuing Operating Activities	-38	-48	-18	-41	27	-42	-40	-42	-49	-61	-63
Net Income / (Loss) Continuing Operations	-47	-41	-24	-37	-42	-42	-45	-49	-59	-56	-43
Consolidated Net Income / (Loss)	-47	-41	-24	-37	-42	-42	-45	-49	-59	-56	-43
Depreciation Expense	1.62	1.75	1.90	1.95	1.93	2.05	2.33	2.39	2.55	2.35	2.24
Amortization Expense	0.77	0.61	0.45	-0.21	-0.15	-0.09	-0.40	-1.95	-1.74	-1.78	0.15
Non-Cash Adjustments To Reconcile Net Income	8.30	8.54	8.76	8.89	8.04	7.82	8.85	9.04	8.54	8.72	10
Changes in Operating Assets and Liabilities, net	-1.92	-19	-5.30	-15	59	-10	-5.94	-2.70	0.45	-14	-32
Net Cash From Investing Activities	55	16	44	23	-14	36	-131	-21	-141	26	71
Net Cash From Continuing Investing Activities	55	16	44	23	-14	36	-131	-21	-141	26	71
Purchase of Property, Plant & Equipment	-2.57	-2.28	-1.08	-2.46	-2.59	-2.88	-1.94	-2.35	-2.11	-3.49	-2.68
Purchase of Investments	-27	-23	-61	-75	-88	-55	-225	-130	-298	-110	-68
Sale and/or Maturity of Investments	84	41	106	100	77	93	96	111	160	139	142
Net Cash From Financing Activities	-0.14	1.48	0.03	1.70	0.01	1.62	238	46	201	1.47	0.01
Net Cash From Continuing Financing Activities	-0.14	1.48	0.03	1.70	0.01	1.62	238	46	201	1.47	0.01
Other Financing Activities, net	0.05	0.03	0.03	0.93	0.01	0.36	0.22	3.04	1.45	0.22	0.01

This table presents Nurix Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	11/30/2019	11/30/2020	11/30/2021	11/30/2022	11/30/2023	11/30/2024
Total Assets	44	396	477	417	356	669
Total Current Assets	39	298	311	318	296	619
Cash & Equivalents	35	119	81	64	55	110
Short-Term Investments	2.90	162	215	245	233	500
Accounts Receivable	-	-	6.00	-	-	0.00
Prepaid Expenses	1.63	5.94	9.19	9.31	7.60	9.80
Plant, Property, & Equipment, net	3.87	6.67	11	17	17	18
Total Noncurrent Assets	0.82	91	154	81	43	32
Other Noncurrent Operating Assets	0.32	0.35	17	17	36	32
Total Liabilities & Shareholders' Equity	44	396	477	417	356	669
Total Liabilities	54	106	134	113	155	142
Total Current Liabilities	16	45	66	71	87	96
Accounts Payable	1.60	3.41	6.65	5.06	6.40	11
Accrued Expenses	4.93	-	15	22	25	38
Current Deferred Revenue	9.61	33	41	38	48	38
Other Current Liabilities	-	-	3.85	5.53	7.49	8.01
Total Noncurrent Liabilities	37	62	68	42	68	46
Noncurrent Deferred Revenue	36	61	59	36	45	26
Other Noncurrent Operating Liabilities	1.74	0.85	9.19	6.43	23	20
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-58	290	342	304	200	527
Total Preferred & Common Equity	-58	290	342	304	200	527
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-58	290	342	304	200	527
Common Stock	2.74	394	564	709	746	1,266
Retained Earnings	-60	-104	-221	-401	-545	-739
Accumulated Other Comprehensive Income / (Loss)	-0.00	0.09	-0.61	-4.32	-0.66	0.15

This table presents Nurix Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025
Period end date	8/31/2022	2/28/2023	5/31/2023	8/31/2023	2/29/2024	5/31/2024	8/31/2024	2/28/2025	5/31/2025
Total Assets	459	370	351	308	313	511	514	615	592
Total Current Assets	355	288	290	268	251	450	456	564	515
Cash & Equivalents	48	34	59	42	50	117	99	76	84
Short-Term Investments	297	244	222	217	194	326	349	474	402
Accounts Receivable	0.00	-	-	2.00	-	-	-	-	19
Prepaid Expenses	10	11	8.84	7.10	6.98	7.08	7.99	14	11
Plant, Property, & Equipment, net	17	18	18	17	18	19	17	18	19
Total Noncurrent Assets	88	64	42	24	44	42	40	33	57
Other Noncurrent Operating Assets	19	16	15	14	34	33	31	33	57
Total Liabilities & Shareholders' Equity	459	370	351	308	313	511	514	615	592
Total Liabilities	117	96	91	74	144	140	137	134	144
Total Current Liabilities	68	65	72	61	88	81	86	90	76
Accounts Payable	6.05	5.63	4.53	2.19	5.92	2.81	3.92	8.40	5.95
Accrued Expenses	20	15	18	22	28	23	28	44	37
Current Deferred Revenue	36	38	44	32	46	47	48	31	27
Other Current Liabilities	5.50	5.56	5.58	5.36	7.31	7.93	6.55	6.64	5.24
Total Noncurrent Liabilities	49	31	18	13	56	60	50	44	68
Noncurrent Deferred Revenue	42	26	15	10	34	39	30	24	22
Other Noncurrent Operating Liabilities	7.75	5.11	3.76	2.64	22	21	21	20	47
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	343	274	260	234	169	371	377	481	448
Total Preferred & Common Equity	343	274	260	234	169	371	377	481	448
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	343	274	260	234	169	371	377	481	448
Common Stock	701	719	728	738	756	1,002	1,057	1,276	1,286
Retained Earnings	-355	-442	-466	-503	-587	-631	-680	-795	-839
Accumulated Other Comprehensive Income / (Loss)	-3.74	-3.25	-1.90	-1.23	-0.35	-0.14	0.34	0.23	-0.02

This table displays calculated financial ratios and metrics derived from Nurix Therapeutics' official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Period end date	11/30/2019	11/30/2020	11/30/2021	11/30/2022	11/30/2023	11/30/2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	-42.73%	66.95%	29.84%	99.31%	-29.15%
EBITDA Growth	0.00%	-212.79%	-76.07%	-56.80%	14.95%	-41.58%
EBIT Growth	0.00%	-192.24%	-81.41%	-55.97%	15.67%	-37.38%
NOPAT Growth	0.00%	-192.24%	-81.41%	-55.97%	15.67%	-37.38%
Net Income Growth	0.00%	-99.28%	-171.02%	-53.90%	20.19%	-34.47%
EPS Growth	0.00%	58.12%	1.09%	-35.90%	28.57%	-8.68%
Operating Cash Flow Growth	0.00%	-113.31%	-105,356.25%	-89.42%	49.09%	-112.11%
Free Cash Flow Firm Growth	0.00%	0.00%	-230.20%	-129.50%	44.64%	-94.34%
Invested Capital Growth	0.00%	-53.82%	-23.37%	23.49%	-36.80%	12.91%
Revenue Q/Q Growth	0.00%	0.00%	2.43%	-1.56%	12.21%	-3.32%
EBITDA Q/Q Growth	0.00%	0.00%	-17.65%	-6.52%	1.84%	-10.82%
EBIT Q/Q Growth	0.00%	0.00%	-17.96%	-6.20%	2.12%	-9.98%
NOPAT Q/Q Growth	0.00%	0.00%	-17.96%	-6.20%	2.12%	-9.98%
Net Income Q/Q Growth	0.00%	0.00%	-17.89%	-5.26%	3.20%	-9.38%
EPS Q/Q Growth	0.00%	0.00%	-5,360.00%	0.00%	2.93%	1.03%
Operating Cash Flow Q/Q Growth	0.00%	-101.05%	-14.11%	-4.61%	44.27%	-77.66%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-6.91%	43.53%	-79.61%
Invested Capital Q/Q Growth	0.00%	0.00%	-0.49%	2.44%	-171.60%	-2.38%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-64.25%	-350.90%	-370.08%	-446.92%	-190.72%	-381.10%
Operating Margin	-71.46%	-364.66%	-396.26%	-476.01%	-201.41%	-390.52%
EBIT Margin	-71.46%	-364.66%	-396.26%	-476.01%	-201.41%	-390.52%
Profit (Net Income) Margin	-69.74%	-242.66%	-393.93%	-466.93%	-186.98%	-354.85%
Tax Burden Percent	101.11%	67.80%	100.11%	100.00%	100.00%	100.14%
Interest Burden Percent	96.51%	98.14%	99.30%	98.09%	92.83%	90.74%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	227.95%	-30.80%	-37.05%	-55.84%	-57.10%	-53.22%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-50.48%	-29.51%	-27.00%	-41.16%	-40.15%	-41.57%
Return on Assets (ROA)	-49.26%	-19.64%	-26.85%	-40.37%	-37.28%	-37.77%
Return on Common Equity (ROCE)	1,382.10%	-25.52%	-37.05%	-55.84%	-57.10%	-53.22%
Return on Equity Simple (ROE_SIMPLE)	37.60%	-14.90%	-34.24%	-59.39%	-71.80%	-36.73%
Net Operating Profit after Tax (NOPAT)	-16	-45	-83	-129	-109	-149
NOPAT Margin	-50.02%	-255.26%	-277.38%	-333.20%	-140.99%	-273.37%
Net Nonoperating Expense Percent (NNEP)	-16.05%	1.12%	-8.71%	-12.82%	-10.59%	-9.82%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-42.38%	-54.14%	-28.30%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	26.76%	91.52%	104.88%	98.37%	55.73%	84.23%
R&D to Revenue	144.71%	373.14%	391.37%	477.64%	245.69%	406.30%
Operating Expenses to Revenue	171.46%	464.66%	496.26%	576.01%	301.41%	490.52%
Earnings before Interest and Taxes (EBIT)	-22	-65	-118	-184	-155	-213
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-20	-63	-110	-173	-147	-208
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	5.71	3.76	1.92	1.50	2.97
Price to Tangible Book Value (P/TBV)	0.00	5.71	3.76	1.92	1.50	2.97
Price to Revenue (P/Rev)	6.72	92.93	43.22	15.12	3.92	28.71
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	7.04	72.05	28.67	5.47	0.08	17.54
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	364.34	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	4.02	-1.43	-1.26	-1.25	-1.33	-1.24
Leverage Ratio	-4.63	1.57	1.38	1.38	1.53	1.41
Compound Leverage Factor	-4.47	1.54	1.37	1.36	1.42	1.28
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-506.30%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	606.30%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.09	9.27	4.95	1.10	-1.50	5.03
Noncontrolling Interest Sharing Ratio	-506.30%	17.17%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	2.44	6.70	4.70	4.51	3.40	6.46
Quick Ratio	2.34	6.31	4.55	4.38	3.31	6.36
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-20	-65	-150	-83	-161
Operating Cash Flow to CapEx	36.40%	-1.76%	-1,490.28%	-1,305.19%	-968.52%	-1,861.15%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.71	0.08	0.07	0.09	0.20	0.11
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	8.04	3.38	3.30	2.71	4.53	3.16
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	-48	-73	-91	-69	-95	-83
Invested Capital Turnover	-0.65	-0.29	-0.36	-0.48	-0.94	-0.61
Increase / (Decrease) in Invested Capital	0.00	-26	-17	21	-26	12
Enterprise Value (EV)	219	1,284	853	211	6.36	957
Market Capitalization	209	1,656	1,286	584	302	1,566
Book Value per Share	($17.53)	$7.47	$7.67	$6.44	$4.13	$7.44
Tangible Book Value per Share	($17.53)	$7.47	$7.67	$6.44	$4.13	$7.44
Total Capital	-9.52	290	342	304	200	527
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-38	-372	-433	-373	-295	-610
Capital Expenditures (CapEx)	1.65	4.55	5.66	12	8.40	9.27
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	-27	-51	-61	-79	-86
Debt-free Net Working Capital (DFNWC)	23	254	245	248	209	524
Net Working Capital (NWC)	23	254	245	248	209	524
Net Nonoperating Expense (NNE)	6.13	-2.25	35	52	35	44
Net Nonoperating Obligations (NNO)	-38	-364	-433	-373	-295	-610
Total Depreciation and Amortization (D&A)	2.25	2.45	7.79	11	8.23	5.14
Debt-free, Cash-free Net Working Capital to Revenue	-46.61%	-152.93%	-170.96%	-158.82%	-103.09%	-157.75%
Debt-free Net Working Capital to Revenue	74.62%	1,424.78%	823.06%	641.50%	270.88%	959.75%
Net Working Capital to Revenue	74.62%	1,424.78%	823.06%	641.50%	270.88%	959.75%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($2.76)	($2.73)	($3.71)	($2.65)	($2.88)
Adjusted Weighted Average Basic Shares Outstanding	0.00	38.91M	44.74M	48.61M	54.34M	67.12M
Adjusted Diluted Earnings per Share	$0.00	($2.76)	($2.73)	($3.71)	($2.65)	($2.88)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	38.91M	44.74M	48.61M	54.34M	67.12M
Adjusted Basic & Diluted Earnings per Share	$0.00	($2.76)	($2.73)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	15.67M	42.90M	47.27M	48.89M	75.89M
Normalized Net Operating Profit after Tax (NOPAT)	-16	-45	-83	-129	-109	-149
Normalized NOPAT Margin	-50.02%	-255.26%	-277.38%	-333.20%	-140.99%	-273.37%
Pre Tax Income Margin	-68.97%	-357.90%	-393.49%	-466.93%	-186.98%	-354.36%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Nurix Therapeutics' official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	11/30/2022	2/28/2023	5/31/2023	8/31/2023	11/30/2023	2/29/2024	5/31/2024	8/31/2024	11/30/2024	2/28/2025	5/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-8.29%	31.85%	168.33%	71.13%	123.49%	30.75%	-60.58%	-31.84%	-12.37%	11.26%	264.34%
EBITDA Growth	-29.57%	-1.60%	42.71%	12.52%	5.96%	-6.58%	-90.84%	-41.54%	-46.62%	-43.99%	1.46%
EBIT Growth	-28.29%	-0.49%	41.45%	14.35%	6.89%	-5.28%	-81.36%	-36.49%	-42.62%	-39.02%	0.45%
NOPAT Growth	-28.29%	-0.49%	41.45%	14.35%	6.89%	-5.28%	-81.36%	-36.49%	-42.62%	-39.02%	0.45%
Net Income Growth	-23.91%	4.23%	46.53%	19.09%	10.19%	-1.93%	-83.49%	-32.38%	-39.55%	-35.73%	2.43%
EPS Growth	0.00%	21.05%	55.45%	24.44%	9.41%	-1.33%	-57.78%	1.47%	3.90%	11.84%	26.76%
Operating Cash Flow Growth	-22.79%	-13.66%	43.89%	11.18%	170.32%	13.42%	-114.98%	-2.54%	-282.66%	-45.62%	-59.08%
Free Cash Flow Firm Growth	-488.93%	3.38%	-8.07%	-23.83%	88.76%	104.02%	98.33%	111.73%	-824.26%	-2,696.61%	-8,794.76%
Invested Capital Growth	23.49%	35.37%	40.64%	50.86%	-36.80%	-65.95%	-67.96%	-131.03%	12.91%	19.61%	53.34%
Revenue Q/Q Growth	-37.14%	87.01%	141.83%	-39.80%	-17.91%	9.41%	-27.09%	4.10%	5.53%	38.91%	138.75%
EBITDA Q/Q Growth	-5.84%	12.34%	39.83%	-56.72%	-13.77%	0.65%	-7.74%	-16.23%	-17.86%	2.43%	26.27%
EBIT Q/Q Growth	-4.22%	11.78%	37.69%	-49.49%	-13.30%	0.25%	-7.34%	-12.51%	-18.40%	2.77%	23.13%
NOPAT Q/Q Growth	-4.22%	11.78%	37.69%	-49.49%	-13.30%	0.25%	-7.34%	-12.51%	-18.40%	2.77%	23.13%
Net Income Q/Q Growth	-2.21%	12.81%	40.40%	-52.33%	-13.45%	1.04%	-7.29%	-9.90%	-19.60%	3.75%	22.87%
EPS Q/Q Growth	5.56%	11.76%	40.00%	-51.11%	-13.24%	1.30%	6.58%	5.63%	-10.45%	9.46%	22.39%
Operating Cash Flow Q/Q Growth	18.04%	-27.66%	61.88%	-122.71%	164.88%	-257.18%	5.35%	-6.23%	-15.59%	-25.30%	-3.40%
Free Cash Flow Firm Q/Q Growth	-6.87%	-5.24%	10.60%	-23.14%	90.30%	137.62%	-137.21%	963.75%	-864.37%	-5.69%	-27.47%
Invested Capital Q/Q Growth	2.44%	25.65%	5.48%	28.33%	-171.60%	9.81%	4.34%	1.42%	-2.38%	16.74%	44.48%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-682.63%	-319.98%	-79.61%	-207.25%	-287.26%	-260.84%	-385.44%	-430.34%	-480.63%	-337.58%	-104.24%
Operating Margin	-717.82%	-338.60%	-87.25%	-216.67%	-299.06%	-272.65%	-401.42%	-433.83%	-486.73%	-340.67%	-109.68%
EBIT Margin	-717.82%	-338.60%	-87.25%	-216.67%	-299.06%	-272.65%	-401.42%	-433.83%	-486.73%	-340.67%	-109.68%
Profit (Net Income) Margin	-688.74%	-321.11%	-79.14%	-200.26%	-276.77%	-250.33%	-368.39%	-388.91%	-440.75%	-305.38%	-98.66%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.22%	100.20%	100.17%	100.01%	100.00%	101.78%
Interest Burden Percent	95.95%	94.83%	90.70%	92.43%	92.55%	91.62%	91.59%	89.49%	90.54%	89.64%	88.37%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-55.84%	-61.58%	-59.79%	-51.60%	-57.10%	-65.37%	-52.33%	-57.96%	-53.22%	-64.16%	-50.67%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-62.06%	-34.95%	-14.27%	-38.74%	-59.62%	-64.60%	-58.05%	-59.57%	-51.81%	-41.43%	-17.58%
Return on Assets (ROA)	-59.55%	-33.14%	-12.95%	-35.80%	-55.18%	-59.31%	-53.27%	-53.40%	-46.91%	-37.14%	-15.82%
Return on Common Equity (ROCE)	-55.84%	-61.58%	-59.79%	-51.60%	-57.10%	-65.37%	-52.33%	-57.96%	-53.22%	-64.16%	-50.67%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-65.16%	-60.57%	-63.60%	0.00%	-85.77%	-44.51%	-46.96%	0.00%	-43.33%	-46.32%
Net Operating Profit after Tax (NOPAT)	-34	-30	-19	-28	-32	-32	-34	-38	-45	-44	-34
NOPAT Margin	-502.48%	-237.02%	-61.08%	-151.67%	-209.34%	-190.86%	-281.00%	-303.68%	-340.71%	-238.47%	-76.78%
Net Nonoperating Expense Percent (NNEP)	-3.14%	-3.00%	-1.69%	-2.63%	-3.06%	-3.40%	-2.78%	-2.95%	-2.94%	-3.07%	-2.05%
Return On Investment Capital (ROIC_SIMPLE)	-11.22%	-	-	-	-15.83%	-	-	-	-8.59%	-9.15%	-7.56%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	138.10%	77.42%	38.07%	57.52%	71.11%	71.14%	96.84%	93.09%	80.68%	63.16%	32.42%
R&D to Revenue	679.73%	361.18%	149.18%	259.14%	327.94%	301.51%	404.58%	440.75%	506.05%	377.52%	177.27%
Operating Expenses to Revenue	817.82%	438.60%	187.25%	316.67%	399.06%	372.65%	501.42%	533.83%	586.73%	440.67%	209.68%
Earnings before Interest and Taxes (EBIT)	-49	-43	-27	-40	-45	-45	-49	-55	-65	-63	-48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-46	-41	-24	-38	-44	-43	-47	-54	-64	-62	-46
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.92	1.63	1.85	1.75	1.50	3.55	2.09	4.31	2.97	2.44	1.81
Price to Tangible Book Value (P/TBV)	1.92	1.63	1.85	1.75	1.50	3.55	2.09	4.31	2.97	2.44	1.81
Price to Revenue (P/Rev)	15.12	10.69	7.88	5.97	3.92	7.41	12.43	28.77	28.71	20.78	9.17
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	5.47	2.88	2.81	2.05	0.08	4.26	5.16	20.66	17.54	11.04	3.67
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.25	-1.23	-1.25	-1.18	-1.33	-1.31	-1.21	-1.19	-1.24	-1.24	-1.15
Leverage Ratio	1.38	1.39	1.41	1.33	1.53	1.54	1.37	1.35	1.41	1.43	1.35
Compound Leverage Factor	1.33	1.32	1.28	1.23	1.42	1.41	1.25	1.20	1.28	1.28	1.19
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.17	1.57	1.98	1.62	-0.48	0.28	2.26	5.89	5.76	4.11	2.16
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.51	4.44	4.01	4.36	3.40	2.86	5.57	5.28	6.46	6.26	6.82
Quick Ratio	4.38	4.27	3.89	4.24	3.31	2.78	5.49	5.19	6.36	6.11	6.68
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-55	-58	-52	-64	-6.22	2.34	-0.87	7.52	-58	-61	-77
Operating Cash Flow to CapEx	-1,479.73%	-2,127.89%	-1,710.09%	-1,672.75%	1,032.46%	-1,454.61%	-2,049.82%	-1,797.06%	-2,315.96%	-1,752.86%	-2,361.16%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.09	0.10	0.16	0.18	0.20	0.24	0.14	0.14	0.11	0.12	0.16
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.71	2.67	3.58	4.15	4.53	4.55	3.36	3.35	3.16	3.11	4.74
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-69	-52	-49	-35	-95	-86	-82	-81	-83	-69	-38
Invested Capital Turnover	-0.48	-0.64	-0.93	-1.29	-0.94	-1.18	-0.95	-0.98	-0.61	-0.73	-1.47
Increase / (Decrease) in Invested Capital	21	28	33	36	-26	-34	-33	-46	12	17	44
Enterprise Value (EV)	211	120	172	141	6.36	345	322	1,166	957	623	325
Market Capitalization	584	446	480	410	302	599	774	1,623	1,566	1,172	810
Book Value per Share	$6.44	$5.80	$5.48	$4.85	$4.13	$3.07	$7.54	$5.85	$7.44	$6.34	$5.87
Tangible Book Value per Share	$6.44	$5.80	$5.48	$4.85	$4.13	$3.07	$7.54	$5.85	$7.44	$6.34	$5.87
Total Capital	304	274	260	234	200	169	371	377	527	481	448
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-373	-326	-309	-269	-295	-254	-453	-458	-610	-550	-486
Capital Expenditures (CapEx)	2.57	2.28	1.08	2.46	2.59	2.88	1.94	2.35	2.11	3.49	2.68
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-61	-54	-63	-52	-79	-81	-74	-78	-86	-76	-46
Debt-free Net Working Capital (DFNWC)	248	223	218	206	209	163	369	370	524	474	440
Net Working Capital (NWC)	248	223	218	206	209	163	369	370	524	474	440
Net Nonoperating Expense (NNE)	13	11	5.54	8.97	10	9.86	11	11	13	12	9.64
Net Nonoperating Obligations (NNO)	-373	-326	-309	-269	-295	-254	-453	-458	-610	-550	-486
Total Depreciation and Amortization (D&A)	2.39	2.36	2.34	1.74	1.79	1.96	1.93	0.44	0.81	0.57	2.40
Debt-free, Cash-free Net Working Capital to Revenue	-158.82%	-128.79%	-104.09%	-76.37%	-103.09%	-99.70%	-118.29%	-138.78%	-157.75%	-134.65%	-52.12%
Debt-free Net Working Capital to Revenue	641.50%	535.97%	357.35%	300.91%	270.88%	201.94%	592.97%	655.30%	959.75%	839.67%	497.52%
Net Working Capital to Revenue	641.50%	535.97%	357.35%	300.91%	270.88%	201.94%	592.97%	655.30%	959.75%	839.67%	497.52%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.85)	($0.75)	($0.45)	($0.68)	($0.77)	($0.76)	($0.71)	($0.67)	($0.74)	($0.67)	($0.52)
Adjusted Weighted Average Basic Shares Outstanding	48.61M	54.03M	54.26M	54.39M	54.34M	54.90M	62.38M	72.78M	67.12M	83.56M	83.88M
Adjusted Diluted Earnings per Share	($0.85)	($0.75)	($0.45)	($0.68)	($0.77)	($0.76)	($0.71)	($0.67)	($0.74)	($0.67)	($0.52)
Adjusted Weighted Average Diluted Shares Outstanding	48.61M	54.03M	54.26M	54.39M	54.34M	54.90M	62.38M	72.78M	67.12M	83.56M	83.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	47.27M	47.45M	48.20M	48.50M	48.89M	49.15M	64.41M	70.84M	75.89M	76.24M	76.45M
Normalized Net Operating Profit after Tax (NOPAT)	-34	-30	-19	-28	-32	-32	-34	-38	-45	-44	-34
Normalized NOPAT Margin	-502.48%	-237.02%	-61.08%	-151.67%	-209.34%	-190.86%	-281.00%	-303.68%	-340.71%	-238.47%	-76.78%
Pre Tax Income Margin	-688.74%	-321.11%	-79.14%	-200.26%	-276.77%	-249.79%	-367.65%	-388.26%	-440.69%	-305.38%	-96.93%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

Nurix Therapeutics (NASDAQ: NRIX) has reported its financial results through Q2 2025, showing continuing trends from the last four years. Here is an analysis of the key financial trends and metrics for investors:

Operating revenue has increased in recent quarters, reaching $44.1 million in Q2 2025, up from $12.1 million in Q2 2024, indicating improving top-line growth.
The company has maintained strong gross profit margins, with total gross profit matching total revenue due to no recorded cost of revenue.
Cash and short-term investments together total approximately $485 million as of Q2 2025 ($84 million cash + $401 million short-term investments), providing Nurix with substantial liquidity.
Net cash from investing activities turned positive in recent quarters, e.g., $71.5 million in Q2 2025, reflecting sales or maturities of investments outpacing purchases, which supports cash reserves.
Weighted average shares outstanding have increased modestly over time, from about 47 million in Q4 2022 to approximately 84 million in Q2 2025, which dilutes earnings per share but may indicate capital raises to fund operations.

Research and development expenses remain high relative to revenues, with $78.1 million in R&D in Q2 2025, reflecting ongoing investment in drug development but pressuring profitability.
The company continues to operate at an operating loss and net loss, though the net loss narrowed from $58.5 million in Q4 2024 to $43.5 million in Q2 2025, suggesting some progress toward profitability.
Selling, General & Administrative expenses have increased but at a slower rate than revenue, reaching $14.3 million in Q2 2025 compared to $11.7 million in Q2 2024, indicative of scaling operations.

Nurix has reported net losses every quarter in the last four years, with Q2 2025 net loss of $43.5 million, highlighting ongoing challenges in achieving profitability.
Negative cash flow from operating activities persists with $63.2 million used in Q2 2025, signaling that the core business is not yet cash flow positive and depends on funding and investments.
Retained earnings remain deeply negative, amounting to -$838.6 million as of Q2 2025, reflecting accumulated losses over time that impact equity and future dividends potential.

Summary: Nurix Therapeutics shows improving revenue growth and strong liquidity positioning, supported by substantial cash and investments. However, the company continues to incur significant losses, driven by heavy R&D expenses and operating costs, common for biotechs in development stages. Investors should watch for continuing revenue improvements, reduction in net losses, and progress in operating cash flow conversion to assess the path toward profitability.

08/25/25 05:18 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Nurix Therapeutics' Financials

When does Nurix Therapeutics' financial year end?

According to the most recent income statement we have on file, Nurix Therapeutics' fiscal year ends in November. Their fiscal year 2024 ended on November 30, 2024.

How has Nurix Therapeutics' net income changed over the last 5 years?

Nurix Therapeutics' net income appears to be on an upward trend, with a most recent value of -$193.57 million in 2024, rising from -$21.70 million in 2019. The previous period was -$143.95 million in 2023. Find out what analysts predict for Nurix Therapeutics in the coming months.

What is Nurix Therapeutics' operating income?

Nurix Therapeutics' total operating income in 2024 was -$213.03 million, based on the following breakdown:

Total Gross Profit: $54.55 million
Total Operating Expenses: $267.58 million

How has Nurix Therapeutics' revenue changed over the last 5 years?

Over the last 5 years, Nurix Therapeutics' total revenue changed from $31.12 million in 2019 to $54.55 million in 2024, a change of 75.3%.

How much debt does Nurix Therapeutics have?

Nurix Therapeutics' total liabilities were at $142.35 million at the end of 2024, a 8.2% decrease from 2023, and a 165.7% increase since 2019.

How much cash does Nurix Therapeutics have?

In the past 5 years, Nurix Therapeutics' cash and equivalents has ranged from $34.82 million in 2019 to $119.36 million in 2020, and is currently $110.00 million as of their latest financial filing in 2024.

How has Nurix Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Nurix Therapeutics' book value per share changed from -17.53 in 2019 to 7.44 in 2024, a change of -142.4%.

Related Companies

This page (NASDAQ:NRIX) was last updated on 8/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nurix Therapeutics (NRIX) Financials

Key Financial Trends

Frequently Asked Questions About Nurix Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nurix Therapeutics (NRIX) Financials

Annual Income Statements for Nurix Therapeutics

Quarterly Income Statements for Nurix Therapeutics

Annual Cash Flow Statements for Nurix Therapeutics

Quarterly Cash Flow Statements for Nurix Therapeutics

Annual Balance Sheets for Nurix Therapeutics

Quarterly Balance Sheets for Nurix Therapeutics

Annual Metrics And Ratios for Nurix Therapeutics

Quarterly Metrics And Ratios for Nurix Therapeutics

Key Financial Trends

Frequently Asked Questions About Nurix Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools